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Abstract
Introduction: The accuracy of preoperative lymph-node staging in patients with adenocarcinoma of the esophagogastric junction (AEG) or
gastric cancer (GC) is low. The aim of this study was to assess the accuracy of [18F]fluorodeoxyglucose positron emission tomography/
computed tomography (PET-CT) for lymph-node staging in patients with AEG or GC, with or without neoadjuvant treatment.
Patients and methods: 221 consecutive patients with GC (n ¼ 88) or AEG (n ¼ 133) were evaluated. Initial staging included endoscopic
ultrasound (EUS), multidetector spiral CT (MDCT) and PET-CT. PET-CT was performed for restaging in patients after neoadjuvant treat-
ment (n ¼ 94). Systematic lymphadenectomy was routinely performed with histopathological assessment of individual mediastinal and
abdominal lymph-node stations. Preoperative staging from EUS, MDCT, and PET-CT was correlated with histopathological results.
Results: PET-CT showed a high specificity (91%) and positive predictive value (89%) for the preoperative detection of lymph-node me-
tastases. In comparison, EUS was more sensitive (73% versus 50%, P < 0.01) but less specific (60%, P < 0.01). In patients with
intestinal/mixed-type tumors, PET-CT improved the detection of extra-regional lymph-node metastases (P ¼ 0.01) and distant metastases
(P ¼ 0.01) compared to CT alone. In contrast, lymph-node assessment by PET/CT after neoadjuvant treatment (32%, P < 0.01) and in
diffuse-type cancers (24%, P < 0.01) is futile because of low sensitivities.
Conclusion: PET-CT does not improve the overall accuracy of N staging, but does improve specificity compared to EUS and MDCT in
AEG and GC. We do not recommend routine PET-CT for the initial staging in patients with diffuse-type cancer or for restaging of lymph
nodes after neoadjuvant treatment.
 2016 Published by Elsevier Ltd.
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Introduction
Adenocarcinomas of the stomach (gastric cancer, GC)
and esophagogastric junction (AEG) (types IeIII according
to the Siewert classification1) are among the most lethal
tumors worldwide.2,3 Lymph-node status is a major prog-
nostic factor,4 and the influence of extended
Abbreviations: AEG, adenocarcinoma of the esophagogastric junction;
CT, computed tomography; EUS, endoscopic ultrasound; GC, gastric
cancer; LAD, lymphadenectomy; LN, lymph node; MDCT, multidetector
spiral computed tomography; PET, 18-fluorodeoxyglucose (18FDG)
positron emission tomography; PET-CT, combined positron emission
tomography and computed tomography.
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lymphadenectomy (LAD) has been studied in, for example,
patients with Barrett’s cancer (AEG Siewert type I). In
these patients, two-field LAD, including the abdominal
and mediastinal nodes, resulted in a survival advantage of
approximately 10%,5 and was significant when up to eight
positive lymph nodes were present.6 In a Dutch randomized
trial7 in patients with gastric cancer, D2-LAD, compared to
D1-LAD, reduced locoregional recurrence rates and re-
sulted in a significant survival benefit after 15 years of
follow-up.
Current preoperative staging includes endoscopic ultra-
sound (EUS), multidetector spiral computed tomography
(MDCT),8,9 and laparoscopy prior to neoadjuvant treatment
for locally advanced GC and AEG Siewert types IIeIII.10
EUS is considered the most accurate diagnostic modality
for determining tumor invasion (T category), although the ac-
curacy depends on the examiner’s experience, and evaluation
of distant lymph-node stations is not possible.11,12 Despite a
known low sensitivity and specificity, CT is performed for the
assessment of lymph nodes and metastases (N and M cate-
gories).13 In the current clinical setting, prediction of
lymph-node involvement is therefore poor, with a low overall
accuracy, and low positive and negative predictive values.8
PET alone may be of additional diagnostic value when
compared to CT because of its higher specificity, demon-
strated in some series.14,15 However, the main disadvantage
of PET is the low overall sensitivity and spatial resolution.
It is therefore not yet clear whether PET is useful for staging
in every patient.13 Metabolic response assessment of the pri-
mary tumor in patients receiving neoadjuvant therapy corre-
lated with an improved survival after resection.16 This
prognostic information is interesting for a subset of patients.
However, it is unclear whether a PET-based restaging would
allow adaptation of the surgical strategy. So far, EUS has
already been demonstrated to be of little use for restaging af-
ter neoadjuvant treatment.17 The availability of combined
PET-CT scanners provides simultaneous information about
anatomy and cancer metabolism in one image, and may
therefore improve anatomical assignment of PET signals
and preoperative decision-making: i.e. selection of patients
for preoperative chemotherapy or chemoradiation,18,19 tar-
geted or systematic extension of LAD,20,21 limited versus
systematic resection in patients with early cancer,22e24 or so-
phisticated individually tailored approaches.25
The aim of this study was to determine the staging accu-
racy of combined PET and CT, compared to EUS and
MDCT, for N staging of patients with AEG and GC (with
or without neoadjuvant treatment) in a large Western series.
Patients and methods
Patients referred to our institution during the years
2008e2013 with a biopsy-proven adenocarcinoma of the
stomach or AEG Siewert types IeIII were included. Exclu-
sion criteria comprised previous treatment for AEG or GC,
or any previous malignancy. Patients underwent routine
staging procedurese including medical history, physical ex-
amination, laboratory tests, upper gastrointestinal endoscopy
with EUS,MDCT, and PET-CT for initial staginge andwere
presented in a specialized upper gastrointestinal tumor board.
Locally advanced tumors received neoadjuvant chemo-
therapy (ECF18 or FLOT26) or chemoradiation,27 andwere re-
staged by PET-CT 2 weeks after the last chemotherapy cycle
and 4e5 weeks after chemoradiation.
The study was approved by the local ethics committee.
Surgery
Standardized resections were performed, including sys-
tematic D2 lymphadenectomy (LAD) with individual patho-
logical assessment of lymph-node (LN) stations 1e12
(Japanese Gastric Cancer Association),28 and additionally
LAD of the lower mediastinum for AEG types II and III.
The D1 compartment includes perigastric LN stations
1e6; D2 includes stations 7e12 along the celiac axis. In pa-
tients with AEG Siewert type I, a transthoracic en bloc
esophagectomy together with a two-field lymphadenectomy
(extended mediastinal LAD) was the surgical standard.5 All
LNs were separately labeled during the operation according
to their localization in the mediastinum (Japan Esophageal
Society) and abdominal LN compartments (Japanese Gastric
Cancer Association) by P.M.S, who was present at all oper-
ations. LNs outside regional compartments e e.g. the axil-
lary, supraclavicular, or para-aortic e were considered as
“extra-regional” LNs (TNM 7th Edition, AJCC/UICC).29
Extra-regional LNs were biopsied by ultrasound or EUS-
guided fine-needle aspiration, or dissected during surgery
if enlarged (10mm) or PET positive on preoperative scans.
Endoscopic ultrasound
EUS procedures were performed by two gastroenterolo-
gists (P.B. and C.G.) with Olympus echoendoscopes GF UE
160 (ALOKA, Holding Europe, Zug, Switzerland) with a
360 radial scanner (5e10 MHz, balloon contact method)
in combination with an Aloka ProSound alpha 10. An LN
was considered metastatic if the following criteria were
present: hypoechogenic internal echo pattern, sharp borders
and rounded shape, or a diameter 10 mm.30
Imaging by multidetector spiral computed
tomography
Contrast-enhanced MDCT was performed using a 128-
slice dual-source CT (Somatom Definition Flash, Siemens
Healthcare, Forchheim, Germany) or a 64-slice dual-
source CT (Somatom Definition, Siemens Healthcare, For-
chheim, Germany) in all patients. LNs were considered
positive if the short-axis diameter was 10 mm.31
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Imaging by 18FDG positron emission tomography
PET-CT imaging was performed as a clinical procedure
on an in-line system (Discovery LS or Discovery ST; GE
Healthcare). These systems integrate a PET scanner
(Advance Nxi; GE Healthcare) with a multi-slice helical
CT (LightSpeed Plus or LightSpeed 16; GE Healthcare)
allowing for acquisition of co-registered CT and PET im-
ages in one session. In PET-negative tumors, LNs were
considered metastatic according to the criteria used for
CT (short-axis diameter  10 mm) whereas in PET-
positive tumors only LNs with FDG uptake were consid-
ered positive.
Statistical analysis
Data were prospectively collected and entered in an
SPSS database (Version 18.0, Chicago, IL). For categorical
variables the chi-square or Fischer’s exact test were used.
All statistical tests were two-sided. All statistical analyses
were performed using SPSS (Version 18.0, Chicago, IL).
A P-value <0.05 indicated statistical significance.
Results
Patient characteristics
Two hundred and twenty-one consecutive patients with
adenocarcinoma of the stomach or esophagogastric junction
(Siewert type IeIII) were included in this study (Table 1).
The majority of patients presented with advanced (T2e4)
tumors; only 46 patients (21%) had early cancer, defined
by tumor invasion limited to the mucosa/submucosa (uT1)
on EUS. Ninety-four patients (43%) received 3e4 cycles
of neoadjuvant chemotherapy or chemoradiation. Surgery
was finally performed in 193 patients; 28 patients had palli-
ative treatment only because of systematic metastases or
peritoneal carcinomatosis (Supplementary Fig. 1).
PET-CT imaging of the primary tumor
Overall, PET-CT detected the primary tumor in 79% of
patients. Higher detection rates were found for AEG (86%)
compared to GC (70%, P < 0.01), and for intestinal/mixed-
type tumors compared to diffuse-type cancers according to
Lauren’s classification (86% versus 63%, P < 0.01).
PET-CT for preoperative lymph-node staging
Lymph-node staging by EUS, MDCT, and PET-CT was
compared and correlated to staging by histopathology.
Overall, EUS demonstrated the highest sensitivity (73%)
in detecting positive LNs compared to PET-CT (50%)
and MDCT (48%). However, PET-CT had a higher speci-
ficity (91%) and positive predictive value (90%) compared
to EUS and MDCT (Fig. 1). The low accuracy and
predictive values were disappointing for all three modalities
and did not translate into clinically relevant differences.
Looking at the 108 patients that were directly operated,
PET-CT showed a lower sensitivity of 35%, as shown in
Fig. 1, indicating that this group of patients includes earlier
stages than patients with neoadjuvant therapy.
Restaging of lymph nodes by PET-CT after
neoadjuvant therapy
Ninety-four patients received neoadjuvant treatment. We
compared the lymph-node status on the initial PET-CT
Table 1
Clinicopathological features (TNM 7th Edition, AJCC/UICC).29 Overall,
193 patients underwent tumor resection. Radical lymphadenectomy was
defined as D2 for gastric cancer or two-field lymphadenectomy for
AEG I.
Parameter n ¼ 221 %
Age (median, years) 62
Gender
Male 158 71
Female 63 29
Localization
AEG Siewert Type I 66 30
AEG Siewert Type II 38 17
AEG Siewert Type III 29 13
Gastric cancer 88 40
Grading
G1 7 3
G2 86 40
G3 128 58
Lauren’s classification
Intestinal 138 62
Mixed 26 12
Diffuse 57 26
Depth of invasion (EUS) (n ¼ 193)
uT1 46 21
uT2 54 24
uT3 74 34
uT4 19 9
Histopathologic T category (n ¼ 193)
ypT0 8 4.1
pT1 59 30.5
pT2 31 16.0
pT3 76 39.4
pT4 19 9.8
Histopathological N category (n ¼ 193)
pNþ 112 58
pN0 81 42
Metastatic disease
Extra-regional LN 23 10.4
Hematogenic metastases 24 10.2
Peritoneal metastases 22 10
Type of surgery (n ¼ 193)
Transthoracic esophagectomy 45 23
Transmediastinal esophagectomy 19 10
Transhiatally extended gastrectomy 62 32
Total gastrectomy 21 11
Subtotal (4/5) gastrectomy 46 24
Lymphadenectomy
Patients with D2 or two-field LAD 177 92
Number of harvested lymph nodes (median) 36
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prior to chemotherapy or chemoradiation to a second PET-
CT performed for restaging (Fig. 1). After neoadjuvant
treatment, LNs became PET-CT-negative in 37% of pa-
tients. Consequently, in the second PET-CT, the false-
negative rate increased, and the sensitivity dropped to
only 32% (P < 0.001) compared to the initial staging
PET-CT. N staging in patients with neoadjuvant treatment
should therefore always be interpreted on the basis of the
initial PET-CT staging.
N staging according to tumor localization and
Lauren’s subtypes
We compared the accuracy of N staging by PET-CT for
different tumor locations, and found a higher sensitivity
(62% versus 38%, P ¼ 0.01) and accuracy (72% versus
49%, P ¼ 0.07) for AEG tumors compared to gastric cancer
(Table 2). AEG-type tumors showed a higher rate of
intestinal-type carcinomas compared to GC. Indeed, look-
ing at the Lauren type, the accuracy of N staging for
intestinal/mixed-type tumors was significantly better than
for diffuse-type tumors (Table 2). Additionally, we assessed
whether PET-CT improves staging in a specific lymph-node
compartment. However, we found only a poor accuracy in
the D1 and D2 compartments.
PET-CT in the staging of early cancer
Despite a negative predictive value of 79%, PET-CT did
not detect small positive LN metastases in ten patients;
three of them had micrometastases. Compared to MDCT,
PET-CT EUS MDCT
p 
versus
EUS
p 
versus
CT
SensiƟvity 50.0 73.3 47.6 <0.01 0.8
Specificity 91.3 60.8 82.2 <0.01 0.1
Accuracy 66.3 67.5 61.8 0.8 0.4
PPV 89.8 68.5 79.4 <0.01 0.1
NPV 54.3 66.2 52.2 0.1 0.8
PET-CT EUS MDCT
p 
versus
EUS
p 
versus
CT
SensiƟvity 34.5 61.4 29.1 <0.01 0.7
Specificity 100 74.5 91.8 <0.01 0.05
Accuracy 64 68.1 58.7 0.6 0.5
PPV 100 69.2 80 <0.01 0.1
NPV 55.6 67.3 53.6 0.2 0.9
PET-CT EUS MDCT
p 
versus
EUS
p 
versus
CT
66.7 85.7 68 0.05 1
75 37 62.5 0.01 0.5
69.3 66.7 66.2 0.9 0.8
85 67.9 79.1 0.08 0.6
51.4 62.5 48.4 0.6 1
PET-CT p
SensiƟvity 31.8 <0.01
Specificity 83.3 0.7
Accuracy 50.0 0.02
PPV 77.8 0.5
NPV 40.0 0.4
PaƟents undergoing 
direct surgery
PaƟents with neoadjuvant 
treatment
Restaging aŌer neoadjuvant 
treatment
Figure 1. N staging by positron emission tomography and computed tomography (PET-CT), endoscopic ultrasound (EUS) and multidetector spiral computed
tomography (MDCT). Preoperative lymph-node staging was evaluated by PET-CT, EUS and MDCT, and compared to staging by histopathology. Analysis
was performed for the whole cohort of patients using initial staging results, then separately using initial staging for the groups with and without neoadjuvant
treatment, and finally restaging PET-CT following neoadjuvant treatment prior to surgery.
Table 2
N staging according to tumor localization and Lauren’s subtypes. Lymph-
node staging by combined positron emission tomography and computed
tomography (PET-CT) was assessed in adenocarcinoma of the esophago-
gastric junction (AEG) versus gastric cancer (A), and in intestinal versus
diffuse-type carcinomas (B). Mixed types were grouped within intestinal
types.
A AEG IeIII Gastric cancer P
Sensitivity 61.8 38.3 0.01
Specificity 85.7 91.9 0.5
Accuracy 70.9 58.8 0.08
PPV 87.5 88.5 1
NPV 58.1 47.9 0.3
B Intestinal Diffuse P
Sensitivity 58.6 24 <0.01
Specificity 88.9 100 0.6
Accuracy 71.8 48.6 0.02
PPV 87.2 100 1
NPV 62.3 38.7 0.03
PPV, positive predictive value; NPV, negative predictive value.
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PET-CT therefore did not improve lymph-node staging in
pT1 tumors (Table 3).
PET-CT for extra-regional lymph nodes and systemic
metastases
Overall, there was no difference in the detection rate for
systemic metastases by PET-CT and MDCT (Table 4). The
main reason for this, despite a high specificity of both mo-
dalities, was missed peritoneal carcinomatosis. When peri-
toneal metastasis was excluded, the sensitivity of PET-CT
increased significantly compared to that of MDCT (82%
versus 48%, P ¼ 0.01, Table 4). Analyzing only the PET-
sensitive intestinal/mixed-type tumors, the sensitivity for
detecting LN metastases outside regional compartments
further increased and was significantly better for PET-CT
than for MDCT (95% versus 63%, P ¼ 0.01).
Discussion
Our data confirm the moderate diagnostic value of EUS
and CT in preoperative N staging for AEG and GC in this
Western series. The major benefit of the combined PET-CT
is a higher specificity and positive predictive value, partic-
ularly in intestinal/mixed-type tumors. In contrast, staging
of diffuse-type tumors by PET-CT and evaluation of lymph
nodes after neoadjuvant treatment are inaccurate. The
strength of this study is its detailed histopathological anal-
ysis after systematic radical lymphadenectomy, often not
available in other reports. To the best of our knowledge
no large trial with standardized radical LAD using EUS,
CT and integrated PET/CT comparing AEG IeIII and GC
has been reported in a Western population.
The good results of EUS in our study are not uniformly
reproducible in the literature, and some studies demonstrate
a high variability for sensitivity (16.7e96.7%) and specificity
(48.4e100%).13,32 Both EUS and CT generally use a diam-
eter 1 cm as a diagnostic criterion for LN involvement.33
LN size alone, however, is not a reliable indicator in AEG
and GC since more than 50% of resected metastatic LNs
are 5 mm in diameter.34 One study therefore defined all
identifiable LNs as metastatic,35 and surprisingly this study
still reported a sensitivity of 89.5% and a specificity of 75.0%.
In the present study, the major advantage of the PET-CT is
a good specificity and positive predictive value. The vast ma-
jority of previously reported studies were performed with
PETonly, and showed a high specificity, despite a low sensi-
tivity in gastric32 and esophageal cancers.36 A possible
reason for the reported low to moderate sensitivity of PET
is its limited resolution. Current PET scanners have a 4e5-
mm resolution,35 but it has been reported that 15% of meta-
static LNs in gastric cancer have a diameter of <3 mm.34
PET/CT fusion provides both anatomical and functional
information, and theoretically allows more accurate locali-
zation of foci with increased 18FDG uptake than stand-
alone PET. Our results, however, are in line with published
data using conventional PET.14,37e39 Despite the combined
PET-CT used in our study, the sensitivity remained too low
for clinical prediction of regional lymph nodes. This may
be a result of the intense uptake of 18FDG by the primary
tumor that complicates interpretation by obscuring the adja-
cent regional LN basins. Previously, PET alone demon-
strated an improved detection of distant lesions compared
to CT,40,41 and sensitivities as high as 90% have been re-
ported in the detection of metastatic LNs at distant sites,
including cervical and abdominal locations.14 Two recent
reports suggest a role for PET-CT in the detection of met-
astatic disease, but they are retrospective and lack compar-
ison with CT and/or histology.42,43 The only available
prospective study involving 113 Western patients found a
benefit in about 10% of the patients compared to CT.44
Our data strongly support these findings, especially for tu-
mors with intestinal/mixed differentiation. In contrast, PET-
CT does not provide an additional benefit in diffuse-type
cancers or for exclusion of peritoneal involvement, where
diagnostic laparoscopy remains the diagnostic standard.
A recent study in patients with esophageal cancer re-
ported a poor diagnostic performance of a response PET-
CT after chemoradiation.45 This is in line with our results,
and we extended our findings to patients with gastric can-
cer. Importantly, our results show that the initial PET-CT
Table 3
N staging for early versus advanced tumors. N staging by positron emis-
sion tomography and computed tomography (PET-CT): accuracy and pre-
dictive values for early and advanced tumors (TNM 7th Edition, AJCC/
UICC).29
Advanced (>pT1) Early (pT1) P
Sensitivity 49.5 28.6 0.2
Specificity 88.9 95 0.4
Accuracy 58.3 77.8 0.02
PPV 93.9 66.7 0.08
NPV 33.8 79.2 <0.01
PPV, positive predictive value; NPV, negative predictive value.
Table 4
Comparison of positron emission tomography and computed tomography
(PET-CT) and multidetector spiral computed tomography (MDCT) in the
detection of metastases. (A) Overall detection of metastases. (B) Detection
of systemic metastases with exclusion of peritoneal carcinomatosis.
A PET-CT MDCT P
Sensitivity 56.9 40.0 0.1
Specificity 98.7 98.1 1
Accuracy 88.5 83.3 0.1
PPV 93.5 88.0 0.7
NPV 87.6 82.7 0.2
B PET-CT MDCT P
Sensitivity 82.1 48.4 0.01
Specificity 98.9 98.9 1
Accuracy 96.7 91.6 0.04
PPV 92 88.2 1
NPV 97.3 91.9 0.02
PPV, positive predictive value; NPV, negative predictive value.
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scan before neoadjuvant treatment is more accurate for N
staging than the consecutive preoperative PET-CT scan af-
ter neoadjuvant treatment, which showed a high false-
negative rate and is therefore not reliable for the prediction
of lymph-node status. Despite the shown prognostic infor-
mation by response evaluation of the primary tumor in
the MUNICON II trial,16 a restaging PET-CT therefore
does not change the surgical strategy or extent of
lymphadenectomy.
Based on our results, PET-CT should not be uniformly
recommended. For regional N staging, PET-CT is useful
only in patients with AEG tumors or GC with intestinal/
mixed differentiation, where sensitivity and accuracy are
clearly better than those of EUS and MDCT. In these pa-
tients, PET-CT may help to identify extra-regional lymph
nodes for extended surgery. Routine extension of LAD to
the para-aortic D3 compartment did not result in an overall
survival benefit in GC, and is probably indicated only in
selected patients.21 Similarly, three-field LAD for esopha-
geal cancer may improve the outcome in selected patients,
but is currently also not recommended for routine use.20
Radiological staging could be an option to select patients
for targeted extension of the LAD since detection is
improved by both PET14 and PET-CT, as demonstrated.
In contrast, sensitivity is insufficient for decision-making
in patients with gastric cancer with diffuse-type tumors
owing to a low FDG uptake and therefore poor sensitivity.
In early tumors, a limited LAD cannot be recommended on
the basis of PET-CT. The risk of missing small metastases
or micrometastases by PET-CT in these patients is signifi-
cant, and may have an impact on the patients’ survival.46
In conclusion, PET-CT improves diagnostic specificity,
but does not improve overall accuracy compared to EUS
and MDCT, and therefore should not be performed in all
patients with AEG or GC. In patients with AEG or GC
with intestinal/mixed-type differentiation, PET-CT has a
higher specificity and PPV than EUS and MDCT for N
staging, improves the detection rate of extra-regional LNs
and systemic metastases, and influences therapeutic strate-
gies. In patients following neoadjuvant treatment, restaging
of lymph nodes by PET-CT appears to be too inaccurate.
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